What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines
•Most guidelines mentioned non-recommended treatments for the different phases of bipolar disorder;•There is no uniformity in how to define non-recommended treatments and how to inform the readers;•Lamotrigine, gabapentin and topiramate were the most common non-recommended treatments for mania;•Anti...
Gespeichert in:
Veröffentlicht in: | Journal of affective disorders 2022-02, Vol.298 (Pt A), p.565-576 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 576 |
---|---|
container_issue | Pt A |
container_start_page | 565 |
container_title | Journal of affective disorders |
container_volume | 298 |
creator | Gomes, Fabiano A. Cerqueira, Raphael O. Lee, Yena Mansur, Rodrigo B. Kapczinski, Flavio McIntyre, Roger S. Yatham, Lakshmi N. Berk, Michael Milev, Roumen Brietzke, Elisa |
description | •Most guidelines mentioned non-recommended treatments for the different phases of bipolar disorder;•There is no uniformity in how to define non-recommended treatments and how to inform the readers;•Lamotrigine, gabapentin and topiramate were the most common non-recommended treatments for mania;•Antidepressant monotherapy and aripiprazole, risperidone and ziprasidone were non-recommended for bipolar depression.
Clinical practice guidelines (CPG) are an important tool for implementation of evidence-based clinical care. Despite clinical trials showing lack of efficacy of some agents in bipolar disorder (BD), they are still frequently prescribed in clinical practice. The objective of this study was to systematically review the CPG recommendations on pharmacological interventions with evidence against their use due to lack of efficacy data and/or due to serious safety concerns.
A systematic literature search identified 29 guidelines published by national and international organizations during the 1994–2020 period. Information was extracted regarding how the recommendations framed non-use of treatments in particular clinical situations as well as the actual recommendation in the guideline.
Twenty-three guidelines (79%) mentioned at least one non-recommended treatment. The terms used to qualify recommendations varied amongst guidelines and included: “not recommended” “no recommendation” and “negative evidence”. Lamotrigine, topiramate and gabapentin were commonly cited as non-recommended treatments for mania and most CPG did not recommend monotherapy with antidepressants, aripiprazole, risperidone, and ziprasidone for treatment of acute bipolar depression. Most guidelines made recommendations about lack of efficacy data or potential harm in treatments for BD but there is a significant variation in the way this information is conveyed to the reader.
Non-recommended treatments were based on their use for BD episodes or maintenance but specific medications may benefit patients when treating comorbid conditions.
The absence of a uniform language and recommendations in current guidelines may be an additional complicating factor in the implementation of evidence-based treatments in BD. |
doi_str_mv | 10.1016/j.jad.2021.11.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2596452934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032721012258</els_id><sourcerecordid>2596452934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-343f0ffa238f8d024cf715ec2d5ba5dbcbf05c8d1650e34d540e72c25dcf9ceb3</originalsourceid><addsrcrecordid>eNp9kE9PGzEQxa2qqKRpPwAX5GMvu_jPOk7KCSFoKyFxAXG0vONx62h3ndpeEN8eRwk99jSj0Xtv9H6EnHHWcsZXF9t2a10rmOAt5y1j-gNZcKVlIxTXH8mialTDpNCn5HPOW8bYaqPZJ3IqO63WUosFeXn6YwudYqEl0jkjDRPtwy4ONlEXckwOU_5Or2h-zQVHWwLQhM8BX2j01Tc1CSGOI04OHS0Jbal7yfscGMIUwA50lyxUI9Lfc3BYr5i_kBNvh4xfj3NJHm9vHq5_Nnf3P35dX901IJUsjeykZ95bIdd-7ZjowGuuEIRTvVWuh94zBWtXizKUnVMdQy1AKAd-A9jLJfl2yN2l-HfGXMwYMuAw2AnjnI1Qm1WnxKY-WhJ-kEKKOSf0ZpfCaNOr4czseZutqbzNnrfh3FTe1XN-jJ_7Ed0_xzvgKrg8CLCWrNiSyRBwAnShgivGxfCf-DcqmZMJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2596452934</pqid></control><display><type>article</type><title>What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gomes, Fabiano A. ; Cerqueira, Raphael O. ; Lee, Yena ; Mansur, Rodrigo B. ; Kapczinski, Flavio ; McIntyre, Roger S. ; Yatham, Lakshmi N. ; Berk, Michael ; Milev, Roumen ; Brietzke, Elisa</creator><creatorcontrib>Gomes, Fabiano A. ; Cerqueira, Raphael O. ; Lee, Yena ; Mansur, Rodrigo B. ; Kapczinski, Flavio ; McIntyre, Roger S. ; Yatham, Lakshmi N. ; Berk, Michael ; Milev, Roumen ; Brietzke, Elisa</creatorcontrib><description>•Most guidelines mentioned non-recommended treatments for the different phases of bipolar disorder;•There is no uniformity in how to define non-recommended treatments and how to inform the readers;•Lamotrigine, gabapentin and topiramate were the most common non-recommended treatments for mania;•Antidepressant monotherapy and aripiprazole, risperidone and ziprasidone were non-recommended for bipolar depression.
Clinical practice guidelines (CPG) are an important tool for implementation of evidence-based clinical care. Despite clinical trials showing lack of efficacy of some agents in bipolar disorder (BD), they are still frequently prescribed in clinical practice. The objective of this study was to systematically review the CPG recommendations on pharmacological interventions with evidence against their use due to lack of efficacy data and/or due to serious safety concerns.
A systematic literature search identified 29 guidelines published by national and international organizations during the 1994–2020 period. Information was extracted regarding how the recommendations framed non-use of treatments in particular clinical situations as well as the actual recommendation in the guideline.
Twenty-three guidelines (79%) mentioned at least one non-recommended treatment. The terms used to qualify recommendations varied amongst guidelines and included: “not recommended” “no recommendation” and “negative evidence”. Lamotrigine, topiramate and gabapentin were commonly cited as non-recommended treatments for mania and most CPG did not recommend monotherapy with antidepressants, aripiprazole, risperidone, and ziprasidone for treatment of acute bipolar depression. Most guidelines made recommendations about lack of efficacy data or potential harm in treatments for BD but there is a significant variation in the way this information is conveyed to the reader.
Non-recommended treatments were based on their use for BD episodes or maintenance but specific medications may benefit patients when treating comorbid conditions.
The absence of a uniform language and recommendations in current guidelines may be an additional complicating factor in the implementation of evidence-based treatments in BD.</description><identifier>ISSN: 0165-0327</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2021.11.007</identifier><identifier>PMID: 34758372</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antidepressive Agents - therapeutic use ; Antipsychotic Agents - therapeutic use ; Bipolar disorder ; Bipolar Disorder - drug therapy ; Clinical practice guidelines ; Guidelines ; Humans ; Lamotrigine - therapeutic use ; Mania ; Mood disorders ; Risperidone - therapeutic use ; Treatment</subject><ispartof>Journal of affective disorders, 2022-02, Vol.298 (Pt A), p.565-576</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-343f0ffa238f8d024cf715ec2d5ba5dbcbf05c8d1650e34d540e72c25dcf9ceb3</citedby><cites>FETCH-LOGICAL-c353t-343f0ffa238f8d024cf715ec2d5ba5dbcbf05c8d1650e34d540e72c25dcf9ceb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jad.2021.11.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34758372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gomes, Fabiano A.</creatorcontrib><creatorcontrib>Cerqueira, Raphael O.</creatorcontrib><creatorcontrib>Lee, Yena</creatorcontrib><creatorcontrib>Mansur, Rodrigo B.</creatorcontrib><creatorcontrib>Kapczinski, Flavio</creatorcontrib><creatorcontrib>McIntyre, Roger S.</creatorcontrib><creatorcontrib>Yatham, Lakshmi N.</creatorcontrib><creatorcontrib>Berk, Michael</creatorcontrib><creatorcontrib>Milev, Roumen</creatorcontrib><creatorcontrib>Brietzke, Elisa</creatorcontrib><title>What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>•Most guidelines mentioned non-recommended treatments for the different phases of bipolar disorder;•There is no uniformity in how to define non-recommended treatments and how to inform the readers;•Lamotrigine, gabapentin and topiramate were the most common non-recommended treatments for mania;•Antidepressant monotherapy and aripiprazole, risperidone and ziprasidone were non-recommended for bipolar depression.
Clinical practice guidelines (CPG) are an important tool for implementation of evidence-based clinical care. Despite clinical trials showing lack of efficacy of some agents in bipolar disorder (BD), they are still frequently prescribed in clinical practice. The objective of this study was to systematically review the CPG recommendations on pharmacological interventions with evidence against their use due to lack of efficacy data and/or due to serious safety concerns.
A systematic literature search identified 29 guidelines published by national and international organizations during the 1994–2020 period. Information was extracted regarding how the recommendations framed non-use of treatments in particular clinical situations as well as the actual recommendation in the guideline.
Twenty-three guidelines (79%) mentioned at least one non-recommended treatment. The terms used to qualify recommendations varied amongst guidelines and included: “not recommended” “no recommendation” and “negative evidence”. Lamotrigine, topiramate and gabapentin were commonly cited as non-recommended treatments for mania and most CPG did not recommend monotherapy with antidepressants, aripiprazole, risperidone, and ziprasidone for treatment of acute bipolar depression. Most guidelines made recommendations about lack of efficacy data or potential harm in treatments for BD but there is a significant variation in the way this information is conveyed to the reader.
Non-recommended treatments were based on their use for BD episodes or maintenance but specific medications may benefit patients when treating comorbid conditions.
The absence of a uniform language and recommendations in current guidelines may be an additional complicating factor in the implementation of evidence-based treatments in BD.</description><subject>Antidepressive Agents - therapeutic use</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Bipolar disorder</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Clinical practice guidelines</subject><subject>Guidelines</subject><subject>Humans</subject><subject>Lamotrigine - therapeutic use</subject><subject>Mania</subject><subject>Mood disorders</subject><subject>Risperidone - therapeutic use</subject><subject>Treatment</subject><issn>0165-0327</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9PGzEQxa2qqKRpPwAX5GMvu_jPOk7KCSFoKyFxAXG0vONx62h3ndpeEN8eRwk99jSj0Xtv9H6EnHHWcsZXF9t2a10rmOAt5y1j-gNZcKVlIxTXH8mialTDpNCn5HPOW8bYaqPZJ3IqO63WUosFeXn6YwudYqEl0jkjDRPtwy4ONlEXckwOU_5Or2h-zQVHWwLQhM8BX2j01Tc1CSGOI04OHS0Jbal7yfscGMIUwA50lyxUI9Lfc3BYr5i_kBNvh4xfj3NJHm9vHq5_Nnf3P35dX901IJUsjeykZ95bIdd-7ZjowGuuEIRTvVWuh94zBWtXizKUnVMdQy1AKAd-A9jLJfl2yN2l-HfGXMwYMuAw2AnjnI1Qm1WnxKY-WhJ-kEKKOSf0ZpfCaNOr4czseZutqbzNnrfh3FTe1XN-jJ_7Ed0_xzvgKrg8CLCWrNiSyRBwAnShgivGxfCf-DcqmZMJ</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Gomes, Fabiano A.</creator><creator>Cerqueira, Raphael O.</creator><creator>Lee, Yena</creator><creator>Mansur, Rodrigo B.</creator><creator>Kapczinski, Flavio</creator><creator>McIntyre, Roger S.</creator><creator>Yatham, Lakshmi N.</creator><creator>Berk, Michael</creator><creator>Milev, Roumen</creator><creator>Brietzke, Elisa</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220201</creationdate><title>What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines</title><author>Gomes, Fabiano A. ; Cerqueira, Raphael O. ; Lee, Yena ; Mansur, Rodrigo B. ; Kapczinski, Flavio ; McIntyre, Roger S. ; Yatham, Lakshmi N. ; Berk, Michael ; Milev, Roumen ; Brietzke, Elisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-343f0ffa238f8d024cf715ec2d5ba5dbcbf05c8d1650e34d540e72c25dcf9ceb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antidepressive Agents - therapeutic use</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Bipolar disorder</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Clinical practice guidelines</topic><topic>Guidelines</topic><topic>Humans</topic><topic>Lamotrigine - therapeutic use</topic><topic>Mania</topic><topic>Mood disorders</topic><topic>Risperidone - therapeutic use</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gomes, Fabiano A.</creatorcontrib><creatorcontrib>Cerqueira, Raphael O.</creatorcontrib><creatorcontrib>Lee, Yena</creatorcontrib><creatorcontrib>Mansur, Rodrigo B.</creatorcontrib><creatorcontrib>Kapczinski, Flavio</creatorcontrib><creatorcontrib>McIntyre, Roger S.</creatorcontrib><creatorcontrib>Yatham, Lakshmi N.</creatorcontrib><creatorcontrib>Berk, Michael</creatorcontrib><creatorcontrib>Milev, Roumen</creatorcontrib><creatorcontrib>Brietzke, Elisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gomes, Fabiano A.</au><au>Cerqueira, Raphael O.</au><au>Lee, Yena</au><au>Mansur, Rodrigo B.</au><au>Kapczinski, Flavio</au><au>McIntyre, Roger S.</au><au>Yatham, Lakshmi N.</au><au>Berk, Michael</au><au>Milev, Roumen</au><au>Brietzke, Elisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>298</volume><issue>Pt A</issue><spage>565</spage><epage>576</epage><pages>565-576</pages><issn>0165-0327</issn><eissn>1573-2517</eissn><abstract>•Most guidelines mentioned non-recommended treatments for the different phases of bipolar disorder;•There is no uniformity in how to define non-recommended treatments and how to inform the readers;•Lamotrigine, gabapentin and topiramate were the most common non-recommended treatments for mania;•Antidepressant monotherapy and aripiprazole, risperidone and ziprasidone were non-recommended for bipolar depression.
Clinical practice guidelines (CPG) are an important tool for implementation of evidence-based clinical care. Despite clinical trials showing lack of efficacy of some agents in bipolar disorder (BD), they are still frequently prescribed in clinical practice. The objective of this study was to systematically review the CPG recommendations on pharmacological interventions with evidence against their use due to lack of efficacy data and/or due to serious safety concerns.
A systematic literature search identified 29 guidelines published by national and international organizations during the 1994–2020 period. Information was extracted regarding how the recommendations framed non-use of treatments in particular clinical situations as well as the actual recommendation in the guideline.
Twenty-three guidelines (79%) mentioned at least one non-recommended treatment. The terms used to qualify recommendations varied amongst guidelines and included: “not recommended” “no recommendation” and “negative evidence”. Lamotrigine, topiramate and gabapentin were commonly cited as non-recommended treatments for mania and most CPG did not recommend monotherapy with antidepressants, aripiprazole, risperidone, and ziprasidone for treatment of acute bipolar depression. Most guidelines made recommendations about lack of efficacy data or potential harm in treatments for BD but there is a significant variation in the way this information is conveyed to the reader.
Non-recommended treatments were based on their use for BD episodes or maintenance but specific medications may benefit patients when treating comorbid conditions.
The absence of a uniform language and recommendations in current guidelines may be an additional complicating factor in the implementation of evidence-based treatments in BD.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34758372</pmid><doi>10.1016/j.jad.2021.11.007</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-0327 |
ispartof | Journal of affective disorders, 2022-02, Vol.298 (Pt A), p.565-576 |
issn | 0165-0327 1573-2517 |
language | eng |
recordid | cdi_proquest_miscellaneous_2596452934 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Antidepressive Agents - therapeutic use Antipsychotic Agents - therapeutic use Bipolar disorder Bipolar Disorder - drug therapy Clinical practice guidelines Guidelines Humans Lamotrigine - therapeutic use Mania Mood disorders Risperidone - therapeutic use Treatment |
title | What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A10%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20not%20to%20use%20in%20bipolar%20disorders:%20A%20systematic%20review%20of%20non-recommended%20treatments%20in%20clinical%20practice%20guidelines&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Gomes,%20Fabiano%20A.&rft.date=2022-02-01&rft.volume=298&rft.issue=Pt%20A&rft.spage=565&rft.epage=576&rft.pages=565-576&rft.issn=0165-0327&rft.eissn=1573-2517&rft_id=info:doi/10.1016/j.jad.2021.11.007&rft_dat=%3Cproquest_cross%3E2596452934%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2596452934&rft_id=info:pmid/34758372&rft_els_id=S0165032721012258&rfr_iscdi=true |